CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy

BACKGROUND: Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal cancers (CRCs) is not clear yet. METHODS: We assessed 271 surgically-resected stage II...

Descripción completa

Detalles Bibliográficos
Autores principales: Mia-Jan, Khalilullah, Jung, So Young, Kim, Ik-Yong, Oh, Sung Soo, Choi, EunHee, Chang, Sei Jin, Kang, Tae Young, Cho, Mee-Yon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621413/
https://www.ncbi.nlm.nih.gov/pubmed/23537343
http://dx.doi.org/10.1186/1471-2407-13-166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621413/
https://www.ncbi.nlm.nih.gov/pubmed/23537343
http://dx.doi.org/10.1186/1471-2407-13-166

Ejemplares similares